Monash University

Data updated June 26, 2026

Australia

1 Trial1 Event

The Clinical Psychedelic Lab, led by Dr. Paul Liknaitzky, conducts robust clinical trials exploring the efficacy and safety of psychedelic-assisted therapies for various mental health conditions within the Australian healthcare context.

IntroductoryHybridPremiumAcademic programmeContinuing educationLicensed cliniciansAspiring practitionersResearchersOther

Blossom’s read

Monash looks like a serious university-led entrant rather than a commercial psychedelics school: research-first, clinically minded, and explicitly tied to its Clinical Psychedelic Lab and Department of Psychiatry. It appears best suited to clinicians, trainees and academically inclined professionals who want a careful grounding in psychedelic-assisted therapy rather than a flashy practitioner credential. The visible lineage centres on Dr Paul Liknaitzky and a network of national and international educators, researchers and practitioners, with Monash positioning itself towards a future graduate certificate and broader centre of excellence.

Who Monash University is for

Best for health professionals, postgraduate students and globally based learners who want a university-backed introduction to psychedelic therapies and the science around them. It is less about hands-on facilitation and more about building informed literacy, with a pathway towards more advanced study.

Prerequisites

For the Foundations of Psychedelic Therapies short course, Monash states an undergraduate degree or equivalent is required. PSD2002 is only open to students enrolled in an undergraduate course. The planned graduate certificate is described as subject to formal approvals and eligibility, but specific entry conditions were not clearly published in the sources reviewed.

Accreditation & recognition

Monash describes Foundations of Psychedelic Therapies as an accredited course and a micro-credential worth 6 credit points, which may contribute to a postgraduate degree subject to approval. Monash also says it is part of a planned Graduate Certificate in Psychedelic Therapies, which it hopes will become a gold-standard training pathway in Australia, but the graduate certificate itself is not yet confirmed as live in the sources reviewed.

Cost

Foundations of Psychedelic Therapies is listed at A$3,500. The course is delivered over 12 weeks and includes live sessions that are recorded for asynchronous viewing. The sources do not clearly break out whether the fee includes assessment, materials or any additional certification costs.

What you walk away with

Learners walk away with a university short course and, where approved, 6 credit points towards a Monash postgraduate degree or future graduate certificate pathway. Content outcomes include a grounding in psychedelic compounds, models of care, patient groups, therapist training, screening, safety monitoring, ethical practice, controversies and the therapeutic processes of PAT. It is framed as foundational knowledge rather than clinical authorisation to deliver psychedelic-assisted therapy.

Academic Research

0 papers

Published Papers

Trial Involvement

Distinct Focus Topics

Latest Publication

Unknown

Government funding received

1 grant

MRFF — Psilocybin-assisted psychotherapy for treatment-resistant depression

2022–2027

Medical Research Future Fund (MRFF)A$2,700,000

Psilocybin Treatment-Resistant Depression (TRD)

Part of the A$14.8M MRFF clinical-trials package announced January 2022. Monash-led team evaluates the efficacy of psilocybin-assisted psychotherapy in treatment-resistant depression. PIs from the Monash Clinical Psychedelic Lab.

Source